{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 10:55:0", "close_timestamp": 1637578500039, "created": "22/11/2021 10:55:00", "department": "Department of Art", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "4be7942f-882f-43db-bcbf-f13930e00c16", "open_date_time": "2021-10-22 10:51:44", "open_timestamp": 1637578304447, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Ivermectin can kill COVID-19 within 48 hours', Dr Kylie Wagstaf in Monash University study finds depending on the testing results", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 195592, "what": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Ivermectin", "why": "Ivermectin can kill COVID-19 within 48 hours"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 10:46:27", "close_timestamp": 1637577987341, "created": "22/11/2021 10:46:28", "department": "Department of Art", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "f24a15f2-9812-4870-b1ac-7f75db0700e1", "open_date_time": "2021-10-22 10:38:41", "open_timestamp": 1637577521965, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "US vaccines developer Novavax further demonstrated excellent results from its pivotal vaccine trial.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 465376, "what": "Challenges expected for Novavax' COVID-19 vaccine in USA", "when_happened": "current_month", "where_location": "United States", "who": "US vaccines developer Novavax", "why": "a large number of Novavax will likely be distributed to ountries with a greater need for supply."}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 10:57:0", "close_timestamp": 1637578620147, "created": "22/11/2021 10:57:00", "department": "Department of Art", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "20d60055-f015-422d-a30f-a32fd81e875a", "open_date_time": "2021-10-22 10:55:7", "open_timestamp": 1637578507067, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19, based on researchers' studies", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 113080, "what": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Australian GPs", "why": "to fight COVID-19"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 10:51:34", "close_timestamp": 1637578294787, "created": "22/11/2021 10:51:35", "department": "Department of Art", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "d0d0cdc1-7c38-4761-8693-45c1b0868d86", "open_date_time": "2021-10-22 10:46:42", "open_timestamp": 1637578002815, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan is first country to approve COVID-19 cocktail Ronapreve, which is confirmed to be effective for the multiple variants including Delta variant in non-clinical studies.", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 291972, "what": "Japan is first country to approve COVID-19 cocktail Ronapreve", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Ronapreve", "why": "it is extremely important to prevent new infections with vaccines and to expand the treatment options for people with COVID-19"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 11:7:30", "close_timestamp": 1637579250206, "created": "22/11/2021 11:07:32", "department": "Department of Art", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "6b077089-a9e8-4b5d-a5c5-c08ed4b1d9c2", "open_date_time": "2021-10-22 10:57:8", "open_timestamp": 1637578628836, "summary": "On 2021.03.09, Lab research suggests that Comirnaty, the coronavirus vaccine developed by BioNTech and Pfizer, could be effective against a Brazilian variant of concern. On 03.18, Pfizer to quit making biosimilar in China; sells out to WuXi. Pyxis Oncology in-licenses ADC candidates from Pfizer. Pfizer has made progress in a novel oral antiviral for the disease and they have initiated a study of their coronavirus vaccine in children aged 6-12. And the Latest Pfizer-BioNTech results offer youthful optimism.", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 621370}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_14", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 11:17:26", "close_timestamp": 1637579846866, "created": "22/11/2021 11:17:29", "department": "Department of Art", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "e61f0e2e-c0fe-4173-8eae-ffbf8337d24b", "open_date_time": "2021-10-22 11:7:43", "open_timestamp": 1637579263612, "summary": "AstraZeneca starts mass global rollout of COVID-19 vaccine through COVAX. The European Union launched a legal action against AstraZeneca. The UK-based drugmaker AstraZeneca, its work in oncology is potentially of greater significance. And AstraZeneca came out with results that pleased investors. In the latest update relating to the safety of AstraZeneca, the European Medicines Agency has announced that unusual blood clots with low blood platelets should be listed as very rare side effects of AstraZeneca.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 583254}}}